InMed Pharmaceuticals Inc. (NASDAQ:INM – Get Free Report) saw a significant increase in short interest in June. As of June 15th, there was short interest totalling 150,000 shares, an increase of 252.9% from the May 31st total of 42,500 shares. Based on an average daily volume of 841,300 shares, the days-to-cover ratio is currently 0.2 days.
InMed Pharmaceuticals Stock Performance
Shares of InMed Pharmaceuticals stock remained flat at $0.27 during trading hours on Friday. 286,481 shares of the stock traded hands, compared to its average volume of 1,396,789. The company has a current ratio of 6.58, a quick ratio of 5.80 and a debt-to-equity ratio of 0.07. The company’s fifty day moving average price is $0.27 and its 200-day moving average price is $0.33. InMed Pharmaceuticals has a fifty-two week low of $0.21 and a fifty-two week high of $2.08.
InMed Pharmaceuticals (NASDAQ:INM – Get Free Report) last released its quarterly earnings data on Tuesday, May 14th. The company reported ($0.18) earnings per share (EPS) for the quarter. InMed Pharmaceuticals had a negative net margin of 108.02% and a negative return on equity of 53.42%. The company had revenue of $1.17 million during the quarter.
Institutional Inflows and Outflows
InMed Pharmaceuticals Company Profile
InMed Pharmaceuticals Inc, a clinical stage pharmaceutical company, develops a pipeline of prescription-based products. The company operates through two segments, the InMed and the BayMedica. The InMed segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry.
Read More
- Five stocks we like better than InMed Pharmaceuticals
- 3 Healthcare Dividend Stocks to Buy
- What’s Behind Walgreens Stock Plunge: What Investors Can Do Next
- 3 Tickers Leading a Meme Stock Revival
- MarketBeat Week in Review – 6/24 – 6/28
- What Are Dividend Contenders? Investing in Dividend Contenders
- General Mills Stock Drops After Revenue Miss in Fiscal Q4 2024
Receive News & Ratings for InMed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InMed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.